GLP-1 and diabetes drug costs still turn on coverage
Medicare's temporary $50 Bridge program opened obesity GLP-1 coverage in July, but diabetes patients already on Part D stay under regular plan rules. Prior authorization and 2027 price cuts remain the live cost fights.
Medicare Part D already covers some GLP-1 medicines for type 2 diabetes and related heart risk, CNBC reported ahead of the July launch. What changed on July 1 was separate: the Centers for Medicare & Medicaid Services started the Medicare GLP-1 Bridge, a short demonstration that runs through Dec. 31, 2027. Eligible Part D enrollees can get certain obesity-labeled drugs for a flat $50 monthly copay. CMS's Bridge page says that $50 sits outside the normal Part D deductible and does not count toward a beneficiary's true out-of-pocket tally. Covered products include Novo Nordisk's Wegovy (injection and pill), Eli Lilly's Foundayo pill, and Zepbound in the KwikPen form. Ozempic stays on the diabetes Part D track, and single-dose Zepbound vials are not in the pilot.
Reuters's July explainer set out who can use Bridge: people who do not already qualify for a GLP-1 through Part D for diabetes, sleep apnea, or fatty liver disease, and who meet BMI-plus-condition gates — BMI 35 or higher, or lower BMIs with listed heart, kidney, or prediabetes criteria. A clinician must prescribe the drug and complete prior authorization that certifies lifestyle support. CNBC flagged the same friction: providers submit requests to a central processor, with CMS aiming for reviews in about 72 hours, and clinics and pharmacies braced for a demand surge.
Cost pressure for diabetes patients on Ozempic and related drugs is still a different track. Novo Nordisk said in February it would cut U.S. list prices for Wegovy by up to about 50% and for Ozempic by up to about 35% in January 2027, targeting high-deductible and coinsurance plans. CNBC tied that move to Medicare's negotiated $274 monthly price for Wegovy, Ozempic, and Rybelsus starting the same month. Cash-pay offers still run roughly $149 to $499 a month depending on product and dose, CNBC said — far above the Bridge $50 for eligible seniors.
CNBC, Reuters, and CMS agree Bridge is temporary, prior authorization is required, and diabetes Part D coverage is separate from the obesity pilot. They still differ on emphasis — whether the next risk is clinic capacity and muscle-loss safety for older starters (Reuters), whether coverage survives past 2027 without a permanent law change (CNBC citing KFF), or how large the federal bill grows if millions enroll (Reuters put Medicare's share near $250 a month with billions at stake).
Where outlets agree CNBC, Reuters, and CMS agree the Medicare GLP-1 Bridge offers eligible Part D enrollees certain obesity GLP-1s at $50 a month through Dec. 31, 2027, requires prior authorization, and leaves diabetes patients already covered under Part D on regular plan rules.
Where they differ Reuters stresses clinic readiness, muscle-loss risks for older adults, and long-term federal cost if millions enroll. CNBC stresses temporary coverage after 2027 and the separate January 2027 list-price and Medicare negotiated-price cuts for insured diabetes and obesity patients. Whether Bridge becomes permanent coverage remains open on the public record.